Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BCEL |
---|---|---|
09:32 ET | 5657 | 0.0764 |
09:34 ET | 78166 | 0.0693 |
10:06 ET | 900 | 0.071 |
10:32 ET | 2120 | 0.0715 |
10:39 ET | 320 | 0.073 |
10:55 ET | 1233 | 0.074 |
11:29 ET | 100 | 0.075 |
12:27 ET | 500 | 0.081 |
12:56 ET | 3666 | 0.0753 |
01:03 ET | 300 | 0.085 |
01:08 ET | 400 | 0.0755 |
01:33 ET | 36329 | 0.075 |
01:46 ET | 5000 | 0.081 |
01:48 ET | 4500 | 0.081 |
02:24 ET | 1520 | 0.085 |
03:25 ET | 400 | 0.08 |
03:27 ET | 5301 | 0.08 |
03:56 ET | 10391 | 0.08 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Atreca Inc | 3.4M | 0.0x | --- |
Psycheceutical Bioscience Inc | 3.4M | -0.1x | --- |
Revelation Biosciences Inc | 3.3M | 0.1x | --- |
Kiromic Biopharma Inc | 3.3M | -0.1x | --- |
Altamira Therapeutics Ltd | 3.1M | -0.1x | --- |
Mustang Bio Inc | 3.5M | -0.1x | --- |
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.02 |
EPS | $-2.49 |
Book Value | $2.01 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.